Stock Track | Summit Therapeutics Plummets 5.01% Intraday as H.C. Wainwright Cuts Target Price Amid Clinical Data Concerns

Stock Track

05/08

Summit Therapeutics PLC's stock plummeted 5.01% during intraday trading on Thursday, extending recent weakness in the biotechnology sector.

The decline follows H.C. Wainwright's decision to cut its target price on the company from $30 to $23, compounding ongoing negative sentiment from the HARMONi-3 study's interim progression-free survival analysis in squamous non-small cell lung cancer, which failed to reach statistical significance. Multiple institutions have since lowered their target prices, creating a negative resonance effect in the market.

The company had previously disclosed that the HARMONi-3 interim data failed to meet success criteria, triggering a significant single-day decline in late April. While the stock had briefly rebounded after some analysts maintained positive ratings, H.C. Wainwright's recent downgrade has again weighed on market confidence. Investors are now looking ahead to the final HARMONi-3 PFS results expected in the second half of the year and the upcoming HARMONi-6 overall survival data presentation at ASCO.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1170799787"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1170799787\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1170799787?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 01:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170799787","market":"us","top_or_hot":-1,"title":"Stock Track | Summit Therapeutics Plummets 5.01% Intraday as H.C. Wainwright Cuts Target Price Amid Clinical Data Concerns","media":"Stock Track","content":"<p>Summit Therapeutics PLC's stock plummeted 5.01% during intraday trading on Thursday, extending recent weakness in the biotechnology sector.</p><p>The decline follows H.C. Wainwright's decision to cut its target price on the company from $30 to $23, compounding ongoing negative sentiment from the HARMONi-3 study's interim progression-free survival analysis in squamous non-small cell lung cancer, which failed to reach statistical significance. Multiple institutions have since lowered their target prices, creating a negative resonance effect in the market.</p><p>The company had previously disclosed that the HARMONi-3 interim data failed to meet success criteria, triggering a significant single-day decline in late April. While the stock had briefly rebounded after some analysts maintained positive ratings, H.C. Wainwright's recent downgrade has again weighed on market confidence. Investors are now looking ahead to the final HARMONi-3 PFS results expected in the second half of the year and the upcoming HARMONi-6 overall survival data presentation at ASCO.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Summit Therapeutics Plummets 5.01% Intraday as H.C. Wainwright Cuts Target Price Amid Clinical Data Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Summit Therapeutics Plummets 5.01% Intraday as H.C. Wainwright Cuts Target Price Amid Clinical Data Concerns\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-05-08 01:15</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Summit Therapeutics PLC's stock plummeted 5.01% during intraday trading on Thursday, extending recent weakness in the biotechnology sector.</p><p>The decline follows H.C. Wainwright's decision to cut its target price on the company from $30 to $23, compounding ongoing negative sentiment from the HARMONi-3 study's interim progression-free survival analysis in squamous non-small cell lung cancer, which failed to reach statistical significance. Multiple institutions have since lowered their target prices, creating a negative resonance effect in the market.</p><p>The company had previously disclosed that the HARMONi-3 interim data failed to meet success criteria, triggering a significant single-day decline in late April. While the stock had briefly rebounded after some analysts maintained positive ratings, H.C. Wainwright's recent downgrade has again weighed on market confidence. Investors are now looking ahead to the final HARMONi-3 PFS results expected in the second half of the year and the upcoming HARMONi-6 overall survival data presentation at ASCO.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMMT","symbol_name":"Summit Therapeutics PLC","start_time":0,"source_url":"","article_id":"1170799787","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170799787","pubTimestamp":1778174117,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Summit Therapeutics PLC's stock plummeted 5.01% during intraday trading on Thursday, extending recent weakness in the biotechnology sector.The decline follows H.C. Wainwright's decision to cut its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMMT":"Summit Therapeutics PLC"},"translate_title":"个股追踪|Summit Therapeutics盘中暴跌5.01%因H.C.由于临床数据担忧，温赖特下调目标价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1},"content_text":"Summit Therapeutics PLC's stock plummeted 5.01% during intraday trading on Thursday, extending recent weakness in the biotechnology sector.The decline follows H.C. Wainwright's decision to cut its target price on the company from $30 to $23, compounding ongoing negative sentiment from the HARMONi-3 study's interim progression-free survival analysis in squamous non-small cell lung cancer, which failed to reach statistical significance. Multiple institutions have since lowered their target prices, creating a negative resonance effect in the market.The company had previously disclosed that the HARMONi-3 interim data failed to meet success criteria, triggering a significant single-day decline in late April. While the stock had briefly rebounded after some analysts maintained positive ratings, H.C. Wainwright's recent downgrade has again weighed on market confidence. Investors are now looking ahead to the final HARMONi-3 PFS results expected in the second half of the year and the upcoming HARMONi-6 overall survival data presentation at ASCO.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}